Get started

Elililly

ELI LILLY has at least +50% upside from here.Eli Lilly (LLY) has been trading within a 5-year Channel Up and last week closed below its 1W MA50 (blue trend-line) for the first time since the week of March 06 2023. Despite the bearish pressure of this Bearish Leg since July 15 2024, that last 1W MA50 closing was the previous Higher Low at the bottom of the Channel Up. The 1W RSI is on a similar level (just below 40.00) with all previous 4 major bottoms and the common characteristic of all was that the stock broke below the 1W MA50 but managed to keep clear and hold the 1W MA100 (green trend-line), practically the most important Support level of the market. If you want a confirmed buy entry, you might want to wait for yet another Bullish Cross on the 1W MACD (as it happened on all previous bottoms), otherwise this buy opportunity is good to go for at least +58% from the bottom (minimum rise among those 4 Bullish Legs). Our Target is $1135. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
4
ELI LILLY: This consolidation is a buy opportunity.Eli Lilly is neutral on its 1D technical outlook (RSI = 52.880, MACD = 1.910, ADX = 25.797) as well as on 1W as for the past 7 weeks it has turned sideways. This consolidation is taking place half-way through the new bullish wave of the Channel Up that started in early 2023. As you see it is supported by the 1W MA50 and every bullish wave in the beginning was almost at +50% but the latest one was +35%. Consequently we expect a minimum of +46.22% from the bottom and that's what we're aiming for (TP = 1,095). See how our prior idea has worked out: ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
ELI LILLY Always a solid buy below its 1D MA50.Eli Lilly (LLY) broke on Friday below its 1D MA50 (blue trend-line) for the first time since August 09. As the stock trades within a long-term Channel Up since the March 01 2023 bottom, every time the price was below the 1D MA50, it didn't stay for long, thus providing the most effective buy entry. Even though it could dip some more as with July's decline (only such case though out of 6 corrections), as long as the 1D MA200 (orange trend-line) holds, we expect the Channel Up to be extended. The initial Higher Highs were closer to the 1.5 Fibonacci Channel extension, the last one however was exactly on the 1.0 Fib. As a result, we will take a more conservative Target on that trend-line, thus turning bullish now and aiming at $1100 by the end of the year. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
Eli Lilly's Zepbound: A Game-Changer for Obesity Treatment?In a groundbreaking move that could redefine the landscape of obesity treatment, Eli Lilly has slashed the price of its weight loss drug, Zepbound, by half. But is this simply a strategic business decision, or is it a beacon of hope for millions struggling with obesity? Join us as we delve into the implications of this bold move and explore the potential impact on the future of weight management. Imagine a world where obesity is no longer a daunting, insurmountable challenge. A world where effective, affordable treatments are accessible to all who need them. Eli Lilly's recent announcement of a significant price reduction for Zepbound brings us closer to that reality. By making this groundbreaking decision, Eli Lilly has not only demonstrated its commitment to patient access but has also sent a powerful message to the broader healthcare industry. This move has the potential to disrupt the status quo, challenging the outdated policies and practices that have hindered progress in obesity treatment. As we explore the implications of Eli Lilly's decision, we must consider the broader context of the obesity epidemic. For decades, obesity has been stigmatized and overlooked as a serious medical condition. Many individuals struggling with weight loss have faced limited treatment options and significant financial burdens. Eli Lilly's move to lower the price of Zepbound could be a game-changer in this regard. By making the drug more affordable, the company is empowering patients to take control of their health and pursue a healthier lifestyle. This could lead to a significant increase in the number of people seeking treatment for obesity, ultimately improving public health outcomes. However, it is important to note that this is just one step in a larger journey. While Eli Lilly's decision is undoubtedly a positive development, more needs to be done to address the systemic issues that contribute to the obesity epidemic. Policymakers, healthcare providers, and communities must work together to create a supportive environment that promotes healthy eating, physical activity, and access to affordable, effective treatments. In conclusion, Eli Lilly's announcement of a price reduction for Zepbound represents a significant milestone in the fight against obesity. By making this drug more accessible, the company is not only helping individuals achieve their weight loss goals but also challenging the broader healthcare system to prioritize obesity treatment.
NYSE:LLYLong
by signalmastermind
ELI LILLY Recovered all losses from its High! What's next?Eli Lilly and Company (LLY) posted a miraculous bullish reversal in the past 2 weeks, recovering yesterday all of the losses of the brutal correction since its July 15 All Time High. Having rebounded on its 1D MA200 (orange trend-line) while the 1D RSI touched the 30.00 oversold barrier for the first time since February 28 2023, we can claim that LLY's Channel Up now sets eyes for its next Higher High. This pattern is best illustrated with the use of the Fibonacci Channel levels. After initially holding the 1.0 Fib as Resistance, the 'ceiling' is now the 1.5 Fib extension, basically has been since September 12 2023. The interesting parameter of this pattern is that every approximately +35.00 to +40.00% rise, the price pulls back or turns sideways (red arc pattern) until it eventually hits the 1D MA50 (blue trend-line). As the stock completes a +35% rise from the bottom, a little above the 1000 mark, we expect it to turn sideways at best. The target after that is $1200, exactly on the 1.0 Fibonacci level, which is still a modest one, considering that the ceiling is now the 1.5 Fib extension, as discussed above. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
Is Eli Lilly's Stock in a Bubble or just a Correction?Eli Lilly & Co. (NYSE: NYSE:LLY ) has been a standout performer in the stock market this year, with its stock price surging by around 50%, far outperforming the S&P 500’s 15% rise. This impressive performance has brought the stock to trade at 63 times its projected 2024 earnings of $13.75 per share. This raises a critical question for investors: Is Eli Lilly's stock overvalued, or is there still room for growth? Stellar Growth Driven by Innovative Drugs Eli Lilly's recent surge can be attributed primarily to the high demand for its obesity drug, Zepbound, and its diabetes drug, Mounjaro. These two drugs alone are expected to bring in $50 billion in annual peak sales. The company is currently facing a shortage of Zepbound and plans to invest $9 billion in a new manufacturing facility to meet this demand. Additionally, Eli Lilly’s pipeline is extensive, with several drugs under clinical trials across various therapeutic areas. One notable approval is Donanemab, an Alzheimer's Disease treatment, which could generate $5 billion in peak sales. Other successful drugs, such as Verzenio and Zyprexa, also contribute to the company’s robust revenue growth. Financial Performance and Future Projections Eli Lilly's revenue is projected to grow from $34 billion in 2023 to over $60 billion by 2026, representing an increase of over 75%. The company's earnings are also expected to more than triple during this period. Despite a 12% decline in net income from $6.2 billion in 2020 to $5.2 billion in 2023, mainly due to increased non-operating expenses and acquisitions, the adjusted net income margin is poised for a rebound. In Q1 2024, Eli Lilly ( NYSE:LLY ) reported an adjusted net margin of 26.6%, up over 500 basis points year-over-year. The company’s investments in R&D and product development are starting to pay off, and adjusted earnings are expected to range between $13.50 and $14.00 per share in 2024, more than double the previous year. Considering these projections and expected margin expansions, Eli Lilly’s adjusted EPS could reach $25 by 2027. If the stock price remains constant, the forward P/E multiple would decrease to 34x in 2026. However, investors are betting on the stock price increasing, resulting in a more modest P/E contraction to about 52x. This scenario would imply a 50% growth in Eli Lilly's stock price to approximately $1,300 over the next three years. Risks and Competition Despite the positive outlook, Eli Lilly faces risks, particularly from increasing competition in the obesity drug market. Competitors like Novo Nordisk, Roche, and Amgen are also making strides in weight-loss treatments. However, the obesity drugs market is projected to grow 16-fold to over $100 billion by 2030, with Eli Lilly and Novo Nordisk likely dominating this space. Is Eli Lilly's Stock in a Bubble? The term "bubble" implies a scenario where asset prices are inflated beyond their intrinsic value, often driven by speculation and a belief that prices will never fall. While Eli Lilly’s stock has seen tremendous gains, rising 656% over the past five years compared to the S&P 500’s 78.4% increase, it does not necessarily mean it is in a bubble. Eli Lilly’s rise is backed by strong fundamentals, significant revenue growth, and promising developments in its drug pipeline. Conclusion Eli Lilly’s stock is not just a result of speculative trading; it is supported by solid business performance and growth prospects. While there are competitive risks, the company’s innovative drug portfolio and strategic investments position it well for continued success. Any dip in Eli Lilly’s stock should be seen as a potential investment opportunity, offering robust long-term gains. The next few years will likely see Eli Lilly continue its upward trajectory, driven by market share gains and regulatory approvals.
NYSE:LLY
by DEXWireNews
ELI LILLY Entering consolidation phase. Wait for the buy signal.Last time we looked at Eli Lilly (LLY) was on March 18 (see chart below) and we got the most out of it as we entered after a 1D MA50 correction and got the most optimal value: Our original target was $1050 calculated according to the % rise of each previous Bullish Leg (+45%) of the +1 year Channel Up but now it appears that the stock won't hit that level during this Leg as we are entering the bottom phase of the Sine Wave. As you can see on the chart (now on the 1W time-frame), this is where LLY typically pulls-back and consolidates (red Rectangle) until the next Bullish Leg begins near the 1D MA100 (red trend-line). As a result, we are closing our bottom buy position and turn neutral on LLY until we approach the 1D MA100 again, starting mid-August. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
1
$LLY look out below $265 bottom coming soonNYSE:LLY looks like it's topping up here. Anytime you see a chart that has gone straight up like this, you know the fall is going to be painful. I think we'll top within the next week or two and then we're going to start the bear market that goes all the way down to $265 before it truly bounces. Why do I think this? If you create a parabola, price is starting to break through it which means we're likely to see a 80%+ correction once the trend changes. On top of this, RSI is in extreme overbought territory. If you're long, I'd set stops where you're comfortable with gains because once this move down happens, months worth of gains will evaporate.
NYSE:LLYShort
by benjihyam
2
ELI LILLY Preparing for the final buy opportunity.Eli Lilly is on a very steady bullish technical outlook on the 1D timeframe (RSI = 62.145, MACD = 9.380, ADX = 18.580) as it has been trading inside a Channel Up since January 2023. The current bullish vessel within this pattern is a Rising Wedge. As you can see, the two Wedges prior have a last break under the 1D MA50 before rallying to a HH at the top of the Channel Up. The 1D RSI has already crossed over its LH trendline so every pullback that comes in the next 2 weeks, is in our opinion the last buy opportunity. Our target is approximatelly a +45% rise (TP = 1000) which is the rise that all bullish structures prior experienced. See how our prior idea has worked out: ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
AMGN Rises as CEO Celebrates Growth in Experimental Obesity DrugAmgen Inc.'s shares ( NASDAQ:AMGN ) rose by 15.9% when the market opened on Friday, marking its biggest intraday rise since July 2009. The company has emerged as a potential competitor to Eli Lilly & Co. and Novo Nordisk A/S, which currently dominate the weight-loss market. Demand for anti-obesity drugs like Zepbound and Wegovy is so strong that Intelligence's estimate for $80 billion in annual sales by 2030 looks conservative. William Blair analyst Matt Phipps sees MariTide as having multi-blockbuster potential, boosting his rating on Amgen stock to outperform. Shares of Denmark's Novo Nordisk fell as much as 5.3% after the Amgen CEO's comments. Optimism over towering sales of its Wegovy and Ozempic drugs have pushed Novo's market value above $500 billion, reinforcing its position as Europe's most valuable listed company. The stock has more than quadrupled since the start of 2020. MariTide has excited investors because it's taken less frequently than the top-selling treatments from Novo and Lilly. Patients given a monthly injection of the drug lost up to 14.5% of their body weight in 12 weeks, according to a small early-stage study published in February in the journal Nature Metabolism. Some people kept weight off for up to 150 days after stopping the drug, the findings showed. Amgen ( NASDAQ:AMGN ) is already investing in building out production capacity for MariTide, even though it's still in mid-stage studies and hasn't been submitted for regulatory approval. Amgen is planning late-stage studies in obesity, obesity-related conditions, and diabetes, likely delivered in a handheld autoinjector used monthly. Amgen will focus on MariTide and discontinue developing another earlier-stage drug called AMG 786.
NASDAQ:AMGNLong
by DEXWireNews
Eli Lilly's Stock Surges 4.77% on Weight-Loss Wonder DrugEli Lilly & Company (NYSE: NYSE:LLY ) has sent shockwaves through the pharmaceutical industry with the meteoric success of its weight-loss drug Zepbound, propelling the company's stock to new heights despite a mixed first-quarter performance. With sales of Zepbound surpassing Wall Street's projections by a staggering margin, Eli Lilly has raised its sales outlook for the year, overshadowing slight revenue dips from other key products. Zepbound's Triumph and Guidance Boost: In a remarkable turn of events, Zepbound emerged as the star performer in Eli Lilly's ( NYSE:LLY ) portfolio, surpassing sales forecasts by a substantial margin. With first-quarter sales reaching $517.4 million, well above the expected $373 million, Zepbound's success has prompted Eli Lilly to raise its sales guidance for the year by a staggering $2 billion. This unexpected surge in demand for the weight-loss drug has underscored Eli Lilly's position as a frontrunner in the pharmaceutical industry and has reignited investor confidence in the company's growth prospects. Challenges and Opportunities in the Diabetes Market: While Zepbound's success has captured headlines, Eli Lilly ( NYSE:LLY ) faces challenges in its diabetes portfolio, particularly with drugs like Mounjaro and Trulicity. Despite a surge in sales for Mounjaro, both drugs fell short of analyst expectations, highlighting the competitive landscape in the diabetes market. However, with plans to expand production significantly in the second half of the year, Eli Lilly remains optimistic about its ability to meet the growing demand for diabetes treatments and capitalize on emerging opportunities in the market. Analyst Insights and Market Response: Analysts have offered mixed assessments of Eli Lilly's performance, with some highlighting the company's robust guidance raise and the continued strength of Zepbound, while others have raised concerns about softer sales in the GLP-1 franchise. However, overall sentiment remains positive, with analysts reaffirming their bullish outlook on Eli Lilly's stock and emphasizing the company's strategic initiatives to drive growth and innovation. Looking Ahead: As Eli Lilly ( NYSE:LLY ) charts its course forward, all eyes are on the continued success of Zepbound and the company's ability to navigate challenges in the diabetes market. With a bolstered sales outlook and a commitment to expanding production capacity, Eli Lilly ( NYSE:LLY ) is poised to capitalize on evolving consumer preferences and emerging opportunities in the pharmaceutical landscape.
NYSE:LLYLong
by DEXWireNews
ELI LILLY Going to $1050 but after a 1D MA50 correction.Eli Lilly (LLY) has basically turned sideways since the February 16 High. The dominant pattern is a Channel Up since the March 07 2023 Low and can be divided into 3 Bullish Waves that delivered rallies between +45% and +52%. Every time the price hit the 1D MA50 (blue trend-line), it was a buy opportunity. The 1D RSI in particular has a Buy Zone, which coincided with all those dip buy opportunities within the Channel Up. As a result, since the stock has already completed a +45% rise from the October 31 2023 Low, we do expect a pull-back to start soon towards the RSI Buy Zone, but only after it rises a little again and forms a Lower High on the RSI, which would be consistent with the previous top formation on the Channel Up. In any case, at any point the RSI hits its Buy Zone, we will position ourselves with a long and aim for a new +45% rise. Rough target from the current projection is $1050. Notice how efficiently the peak and bottom formations are caught by the Sine Waves. A very symmetric pattern for the long-term indeed. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
ELI LILLY Is a -20% correction possible?Eli Lilly (LLY) gave us the best possible buy entry at the bottom of the Channel Up last time we gave a call on it (December 14 2023, see chart below) and not hit our $705.00 Target but also aggressively broke above the pattern: In order to grasp the magnitude of that move, this time we zoom out on the 1W time-frame where we see the long-term pattern since LLY's parabolic move started, in mid 2018 following 3 years of consolidation. The pattern that emerged since is a 6-year logarithmic Channel Up, which since 2023 has gone extremely parabolic. The key characteristic on this long-term price action is the unique pattern that the 1W MACD forms, a Bearish Cross followed by a Bullish Cross. Four such occurrences since 2018 have caused the stock to form a Higher High top at a minimum 2 weeks and maximum 10 weeks after the Bullish Cross. Currently we are on the 3rd week since the latest 1W MACD Bullish Cross and if it extends to 10 weeks, we can technically expect the new top by April 08 2024. However, the 1st red 1W candle following the Bullish Cross on those 4 past occurrences has always been the top, or near it. Given the fact that LLY is so close to the top of the 6-year Channel Up, we can expect that a correction will start soon. The minimum correction has been -17.44% and the maximum -23.23% (2 occasions out of the 4). Also before a new long-term rally started, the price hit the 1W MA50 (blue trend-line). Long-term investors can wait for such a contact before buying again heavily Eli Lilly for a new 12-month run. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
Eli Lilly Stock Soars on Robust Fourth-Quarter PerformanceEli Lilly (NYSE: NYSE:LLY ) has once again defied expectations, propelling its stock to new heights with a stellar fourth-quarter performance that surpassed even the most optimistic forecasts. The pharmaceutical giant's earnings report, released early Tuesday, showcased a remarkable surge in both revenue and adjusted earnings, fueled by the successful launch of its groundbreaking weight loss drug, Zepbound, and buoyed by robust sales of its flagship diabetes treatment, Mounjaro. Earnings Review Earnings figures reveal a standout quarter for Eli Lilly (NYSE: NYSE:LLY ), with adjusted profit soaring to $2.49 per share, significantly outpacing the consensus estimate of $2.30 per share among analysts surveyed by FactSet. This remarkable feat represents a substantial increase from the year-earlier period, where earnings stood at $2.09 per share, underscoring the company's impressive growth trajectory. Revenue Result Similarly, Eli Lilly's (NYSE: NYSE:LLY ) fourth-quarter revenue surged to $9.35 billion, marking a notable 28% increase from the same period last year and surpassing analysts' expectations of $8.95 billion. This remarkable revenue surge can largely be attributed to the stellar performance of Zepbound, the company's newly approved weight loss drug, which generated a staggering $175.8 million in sales during its inaugural quarter on the market. Analysts Views The success of Zepbound has exceeded even the loftiest projections, with analysts predicting the potential for over a billion dollars in sales within its first year alone, positioning it as a potential game-changer in the pharmaceutical industry. Moreover, with its groundbreaking mechanism of action and promising efficacy profile, Zepbound holds the potential to become one of the most significant drugs in Eli Lilly's (NYSE: NYSE:LLY ) portfolio and a major revenue driver in the years to come. The Mounjaro Meanwhile, the continued strong performance of Mounjaro, Eli Lilly's (NYSE: NYSE:LLY ) blockbuster diabetes treatment, further bolstered the company's financials, with fourth-quarter sales soaring to $2.21 billion, far surpassing analysts' expectations. This remarkable growth can be attributed to both increased demand and higher realized prices, underscoring the enduring strength of Eli Lilly's (NYSE: NYSE:LLY ) diabetes franchise. Challenges However, amidst the impressive financial results, Eli Lilly (NYSE: NYSE:LLY ) also faces challenges, notably in its diabetes portfolio, where lower prices for Trulicity and Humalog offset some of the gains from Mounjaro. Despite this setback, the company remains optimistic about its long-term prospects, buoyed by the continued success of its key products and a robust pipeline of innovative therapies. Future Outlook Looking ahead, Eli Lilly (NYSE: NYSE:LLY ) has provided a bullish outlook for the full year, with projected adjusted earnings in the range of $12.20 to $12.70 per share and revenue expected to reach $40.4 billion to $41.6 billion. These optimistic forecasts reflect the company's confidence in its ability to sustain its growth momentum and capitalize on emerging opportunities in the evolving healthcare landscape. Conclusion In conclusion, Eli Lilly's (NYSE: NYSE:LLY ) fourth-quarter performance stands as a testament to its resilience, innovation, and unwavering commitment to advancing patient care. With its groundbreaking therapies and strong financial performance, Eli Lilly (NYSE: NYSE:LLY ) is well-positioned to deliver sustained value to its shareholders while continuing to make a meaningful impact on global healthcare. As Eli Lilly (NYSE: NYSE:LLY ) prepares to engage with investors during its earnings call, all eyes will be on the company as it provides insights into its strategic priorities, pipeline progress, and plans for driving future growth. Amidst a backdrop of rapid innovation and evolving market dynamics, Eli Lilly's (NYSE: NYSE:LLY ) continued success underscores its status as a powerhouse in the pharmaceutical industry and a beacon of hope for patients worldwide.
NYSE:LLYLong
by DEXWireNews
Eli Lilly Breaks New Ground With Weight Loss Drug Offering Eli Lilly - NYSE:LLY Earnings Rep: $2.49 ✅ Exp: $2.29 - 8.45% HIGHER Revenue Rep: $9.35b ✅ Exp: $8.94b - 4.55% HIGHER Company Summary Eli Lilly is the worlds 9th largest company by market cap at $670b and they have reported positive earnings and revenue both coming in higher than expected for Q4 2023. The pharmaceutical giant booked fourth-quarter revenue of $9.35 billion, up 28% from the same period a year ago. A massive result that is reflected in the chart and pre-market surge in price per a share from €706 - €740 👀 Eli develop and manufacture a series of medications with their top drugs being for diabetes and cancer. The diabetes drug Trulicity generated more than $7.4 billion in revenue for Eli Lilly in 2022 accounting for more than one-quarter of the company's top line, which totaled $28.5 billion. Meanwhile for 2023, Trulicity, reported $1.67 billion in revenue. That’s down 14% from the same period a year go however remains a large revenue generator. Mounjaro booked $2.21 billion in sales for the fourth quarter and remains one of the companies core diabetes products. The Q4 2023 results are the first to include sales of Eli Lilly’s new weight loss drug Zepbound, which won FDA approval in early Nov 2023. Zepbound resulted in $175.8 million in sales for Q4. Analysts are expecting a minimum of $1 billion in sales for the 2024 period and some are claiming that Zepbound could become the biggest drug of all time. Do you feel that AI style narrative euphoria building here? Now more importantly, Lets check out this chart The Chart The chart here really caught my attention, its one of thee strongest long term charts I have come across and it keeps making higher double bottoms off higher moving averages. The OBV is increasing still and the support line might be a good line to watch got an entry bounce or a break down (exit) - a trigger level. PUKA
NYSE:LLYLong
by PukaCharts
ELI LILLY targeting $705.00 if the 1D MA100 holds.Eli Lilly (LLY) has been on an incredible run ever since our March 01 buy signal (see chart below) that even broke above Channel Up: We have been strong supporters of the company's fundamentals and those are translated into strong technical bullish patters, offering solid buy opportunities. Another such opportunity exists now as the price is trading around the 1D MA50 (blue trend-line) near the bottom of the 2023 Channel Up. As long as the 1D MA100 (green trend-line), which is exactly on the Channel's bottom, holds, we remain bullish, targeting the 2.382 Fibonacci extension (similar to the May 22 High) at $705.00. If the 1D MA100 breaks though, we will take the loss and sell instead targeting the 1D MA200 (orange trend-line) at $500.00 where a stronger buy opportunity exists. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
ELI LILLY Expected to rally above 700 if these conditions hold.LLY is holding the 1D MA50 on a neutral 1D technical outlook (RSI = 47.021, MACD = 2.060, ADX = 24.740), which indicates a strong demand level for the stock. The 1D RSI which is under a LH trendline shows that the stock price is at a pre bullish breakout accumulation like the last week of July and early August. If it holds the line, we will buy and aim a +30% rise (TP = 710.00), following a regression of -8% on each top. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
1
ELI LILLY Our gem on the verge of making a paradigm shift.Eli Lilly and Company (LLY) has long been one of our best investments a real gem that even withstood and was practically unaffected by the 2022 inflation crisis. For long we have been using the Fibonacci Channel to display LLY's parabolic nature having broken above the 2.0 Fibonacci extension last May. This time the price reversed much quicker than technically expected and is attempting again to break the top (Higher Lows trend-line) of the Channel Up that started in 2020. If it closes above it, then we wil target the 3.0 Fibonacci Channel extension at $700. If it gets rejected and stays within the Channel Up, we will sell and target the recent Support at $520. Note that a break above this 3-year Channel Up may constitute a paradigm shift as the stock has never hit a new upper Fibonacci level that quickly (remember it broke above the 2.0 Fib just 5 months ago). This can transcend LLY into an even more aggressive bullish nature that we can't yet quantify. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
1
ELI LILLY Needs to correct a little more. Massive buy after.Eli Lilly has completed 3 red weeks in a row. The parabolic rise it is seeing for years is seen accurately on this Fibonacci Channel. Every such price peak, pulled back to under the MA100 (1d), which is now at 492.43, in order to gather buyers. Trading Plan: 1. Sell on the current market price. Targets: 1. 490 (between the MA100 (1d) and the Fibonacci 2.0 level. Tips: 1. The MACD (1d) is just formed a Sell Cross. Only once since 2018 has a Sell Cross failed to deliver a sizeable drop. Please like, follow and comment!!
NYSE:LLYShort
by TradingBrokersView
1
ELI LILLY: Possible to start a strong multi week correction.Eli Lilly has seen enormous growth over the past few years and in particularly in 2023. This Channel Up on the log chart's 1W timeframe is the best depiction of the long term trend. The 1W outlook got extremely overbought technically three weeks ago (RSI = 68.989, MACD = 46.590, ADX = 60.019) and is now correcting. The rejection took place at the top of the Channel Up. This is a hint that investors should be exiting LLY and not entering. Historically the most efficient level to buy is on the 1W MA50 with a max extension to the 1W MA100. That is our entry strategy. Don't take chances and take the best possible entry. This stock will reward us enormously in 2024. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYShort
by InvestingScope
4